Employees: 03 (2023.0)Legal category: 5785Size: PMECreation date: 2015-12-24 (10 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINT-MANDRIER-SUR-MER (83430), Var
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELAS PHARMACIE ANDREDOLI-PY : revenue, balance sheet and financial ratios
SELAS PHARMACIE ANDREDOLI-PY is a French company
founded 10 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-MANDRIER-SUR-MER (83430),
this company of category PME
shows in 2022 a revenue of 1.9 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS PHARMACIE ANDREDOLI-PY (SIREN 817854730)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
1 885 299 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
20 886 €
296 €
143 729 €
80 183 €
104 537 €
82 776 €
81 414 €
141 099 €
-56 130 €
EBITDA
N/C
N/C
224 065 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
7.6%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELAS PHARMACIE ANDREDOLI-PY generates positive net income of 21 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
20 886 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 104%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 42%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
104.391%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
42.022%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
-4021.556
1173.531
609.851
385.558
293.399
213.804
136.31
120.251
104.391
Financial autonomy
-2.227
6.939
12.248
18.331
22.998
28.246
36.299
38.738
42.022
Repayment capacity
None
None
None
None
None
None
4.794
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
9.022%
None%
None%
Sector positioning
Debt ratio
104.392024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average
In 2024, the debt ratio of SELAS PHARMACIE ANDREDOLI-PY (104.39) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
42.02%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average+5 pts over 3 years
In 2024, the financial autonomy of SELAS PHARMACIE ANDREDOLI-PY (42.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
4.79 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Average
In 2022, the repayment capacity of SELAS PHARMACIE ANDREDOLI-PY (4.79) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 37.92. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
167.9
183.022
157.386
164.839
237.808
159.792
150.603
42.279
37.916
Interest coverage
None
None
None
None
None
None
4.864
None
None
Sector positioning
Liquidity ratio
37.922024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Watch-17 pts over 3 years
In 2024, the liquidity ratio of SELAS PHARMACIE ANDREDOLI-PY (37.92) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
4.86x2022
2022
Q1: 0.74x
Med: 2.5x
Q3: 5.15x
Good
In 2022, the interest coverage of SELAS PHARMACIE ANDREDOLI-PY (4.9x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELAS PHARMACIE ANDREDOLI-PY
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
180 310 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
39
0
0
Customer payment term (days)
0
0
0
0
0
0
5
0
0
Supplier payment term (days)
0
0
0
0
0
0
47
0
0
Positioning of SELAS PHARMACIE ANDREDOLI-PY in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELAS PHARMACIE ANDREDOLI-PY is estimated at
291 584 €
(range 203 054€ - 436 226€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
203k€291k€436k€
291 584 €Range: 203 054€ - 436 226€
NAF 5 année 2024
Valuation method used
Net Income Multiple
20 886 €
×
14.0x
=291 584 €
Range: 203 054€ - 436 226€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS PHARMACIE ANDREDOLI-PY with other companies in the same sector:
Frequently asked questions about SELAS PHARMACIE ANDREDOLI-PY
What is the revenue of SELAS PHARMACIE ANDREDOLI-PY ?
The revenue of SELAS PHARMACIE ANDREDOLI-PY in 2022 is 1.9 M€.
Is SELAS PHARMACIE ANDREDOLI-PY profitable?
Yes, SELAS PHARMACIE ANDREDOLI-PY generated a net profit of 21 k€ in 2024.
Where is the headquarters of SELAS PHARMACIE ANDREDOLI-PY ?
The headquarters of SELAS PHARMACIE ANDREDOLI-PY is located in SAINT-MANDRIER-SUR-MER (83430), in the department Var.
Where to find the tax return of SELAS PHARMACIE ANDREDOLI-PY ?
The tax return of SELAS PHARMACIE ANDREDOLI-PY is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS PHARMACIE ANDREDOLI-PY operate?
SELAS PHARMACIE ANDREDOLI-PY operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart